Brief: Hungary Richter says US FDA approves Vraylar as an adjunctive treatment for major depressive disorder

Richter Gedeon Vegyeszeti Gyar Nyrt

19/12/2022 07:13

Dec 19 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt
 GDRB.BU  says:
    * US FDA APPROVES VRAYLAR (CARIPRAZINE) AS AN ADJUNCTIVE
TREATMENT
FOR MAJOR DEPRESSIVE DISORDER
    * APPROVAL MARKS FOURTH INDICATION FOR VRAYLAR
    * VRAYLAR IS NOW THE FIRST AND ONLY DOPAMINE AND SEROTONIN
PARTIAL
AGONIST FDA-APPROVED FOR THE MOST COMMON FORMS OF DEPRESSION
    * CARIPRAZINE IS FDA APPROVED TO TREAT ADULTS WITH
DEPRESSIVE,
ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I
DISORDER AND SCHIZOPHRENIA
    * CARIPRAZINE IS CO-DEVELOPED BY ABBVIE AND RICHTER

Source text for Eikon: [ID: https://bet.hu/newkibdata/128821984/RCH221219ER01E.pdf
]
Further company coverage:  GDRB.BU 
 (Reporting by Krisztina Than and Anita Komuves)
 ((KOMUVES.Anita@thomsonreuters.com;))